The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope - 09/08/11
, Tang Chaoshu, MD
Reprint requests: Du Junbao, MD, Department of Pediatrics, Peking University First Hospital, Xi-An Men Street No. 1, West District, Beijing 100034, People’s Republic of ChinaRésumé |
Objective |
To determine whether midodrine hydrochloride therapy can prevent vasovagal syncope (VVS) in pediatric patients.
Study design |
Children with recurrent syncope (n = 26) were randomly assigned into 2 groups. Group I comprised children given midodrine hydrochloride as first-line therapy in addition to conventional therapy, and group II comprised patients receiving conventional therapy only. Repeat head-up tilt (HUT) testing and follow-up of least 6 months were conducted to evaluate the therapeutic effectiveness and side effects of midodrine in treating VVS in children.
Results |
The HUT-based effective rate was significantly higher in group I than in group II (75% vs 20%; P < .05). During the follow-up period, the recurrence of syncope was significantly lower in group I than in group II (P < .05).
Conclusions |
Midodrine hydrochlorate is effective in treating VVS in children, especially in preventing recurrent episodes. Few side effects were observed in the present study.
Le texte complet de cet article est disponible en PDF.Abbreviations : HUT, VVS
Plan
| Supported by The National Tenth Five-Year Plan Research Project of China (2004BA720A10) and the Major Basic Research Project of China (2006 CB503807). |
Vol 149 - N° 6
P. 777-780 - décembre 2006 Retour au numéro
Article précédent
- Correlates of violent behavior among adolescents presenting to an urban emergency department
- Rebecca Cunningham, Maureen Walton, Matthew Trowbridge, Jim Weber, Ryan Outman, Andy Benway, Ronald Maio
- Exposure to marijuana during pregnancy alters neurobehavior in the early neonatal period
- Marina Carvalho de Moraes Barros, Ruth Guinsburg, Clovis de Araújo Peres, Sandro Mitsuhiro, Elisa Chalem, Ronaldo Ramos Laranjeira
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?